Janus Henderson Group’s Ocular Therapeutix OCUL Stock Holding History

Janus Henderson Group’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$581K	Sell	68,500 -4,160,702	-98%	-$39.7M	﹤0.01%	1947
2025 Q4	$51.3M	Buy	4,229,202 +2,180,702	+106%	+$26.5M	0.02%	411
2025 Q3	$24M	Buy	2,048,500 +1,995,000	+3,729%	+$23.9M	0.01%	567
2025 Q2	$496K	Hold	53,500	–	–	﹤0.01%	1953
2025 Q1	$405K	Hold	53,500	–	–	﹤0.01%	2064
2024 Q4	$457K	Hold	53,500	–	–	﹤0.01%	2075
2024 Q3	$465K	Hold	53,500	–	–	﹤0.01%	2072
2024 Q2	$366K	Buy	+53,500	New	+$330K	﹤0.01%	2118
2022 Q2	–	Sell	-13,076	Closed	-$64K	–	2653
2022 Q1	$64K	Buy	13,076 +3	+0%	+$17	﹤0.01%	2609
2021 Q4	$91K	Buy	+13,073	New	+$102K	﹤0.01%	2511

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Janus Henderson Group's OCUL Position: Q1 2026 in Review

Janus Henderson Group reduced its Ocular Therapeutix (OCUL) stake by 98% in Q1 2026, selling an estimated $39.7M and leaving 68,500 shares worth $581K. The position accounts for ﹤0.01% of the portfolio, ranked #1947.

Janus Henderson Group first reported a position in OCUL in Q4 2021 and has held it in 10 quarters since. The position peaked at $51.3M in Q4 2025. 269 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

Janus Henderson Group held 68,500 shares of Ocular Therapeutix worth $581K as of Q1 2026.
Janus Henderson Group sold 4,160,702 Ocular Therapeutix shares in Q1 2026, an estimated $39.7M.
Ocular Therapeutix made up ﹤0.01% of Janus Henderson Group's portfolio in Q1 2026, its #1947 holding.
Janus Henderson Group first reported a position in Ocular Therapeutix in Q4 2021 and has held it in 10 quarters since.
Janus Henderson Group's Ocular Therapeutix position peaked at $51.3M in Q4 2025.
269 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.